2 results
Approved WMOPending
This Phase 2 study for JNJ-63733657 will assess the possible slowing of cognitive decline seen inprodromal AD and mild AD dementia (Early AD). In addition, effects of JNJ-63733657 on theaccumulation of tau, as measured by tau positron emission…
Approved WMORecruiting
The study*s primary objective is to assess the safety and tolerability of CP-506 alone or in combination therapy. The 3 different modules explore the administration of CP-506: alone (Module 1) or in combination with Carboplatin (Module 2) or in…